论坛上，澳门特别行政区药物监督管理局厅长李志洋将解读澳门特别行政区在"出海落地"方面的制度设 计，探讨如何通过政策支持推动中医药大健康产品走向国际市场。澳门种远科研大健康制造厂质监董事 兼ESG主管郭秀文将介绍在政策创新和海外市场落地方面的尝试与成果。 除政策层面的解读外，前沿医学和科技创新同样是论坛的亮点之一。受邀嘉宾将带来关于细胞科技、组 织再生、脑科疾病修复等方向的研究成果。乌克兰国家科学院院士林哲安将结合共建"一带一路"倡议的 背景，探讨国际医学合作与跨境医疗体系构建的可能路径；原解放军总医院基础医学所组织修复与再生 课题组组长郝好杰将从细胞科技角度，探讨"寿命革命"的科学图景；澳门华圣中医生命科学研究院院长 任连智则将发表脑科疾病修复研究报告。 在论坛的圆桌环节，讨论将更聚焦于跨境实践，议题聚焦粤澳医疗技术创新与跨境科研协作的实践路 径。探讨以澳门为枢纽、横琴为基地，推动粤澳医疗科研资源（如临床转化技术、创新诊疗方案）与共 建"一带一路" 国家医疗需求的精准对接路径；依托横琴产业政策与澳门国际医疗认证优势，研究"科研 成果输出+技术合作+学术交流"的跨境协作模式。 南方财经记者谭海燕 广州报道 9月 ...

Core Viewpoint - China Traditional Chinese Medicine (CTCM) reported a significant decline in net profit by 98.5% for the fiscal year 2024, primarily due to over 100 million yuan in tax payments that severely impacted profitability and highlighted compliance management issues within the company [1][6][7]. Financial Performance - CTCM's revenue for 2024 was 16.51 billion yuan, a decrease of 8.9% year-on-year [4][5]. - The net profit for 2024 was only 20.77 million yuan, marking a drastic drop of 98.5% compared to the previous year [3][5]. - Gross profit fell to approximately 7.86 billion yuan, down 15.3% from 9.27 billion yuan in the previous year, resulting in a gross margin of 47.6%, a decline of 3.6 percentage points [5]. Business Segment Performance - The production and operation of traditional Chinese medicine materials saw a revenue decline of 25.3% [3]. - The Chinese herbal pieces segment experienced a revenue increase of 17.9%, reaching 3.31 billion yuan, although its gross margin was only 23.2% [5]. - The Chinese medicine formula granules segment, once a key revenue driver, saw a 23.5% drop in revenue to 6.97 billion yuan, with a gross margin decrease from 56.9% to 48.3% [5]. Tax Compliance Issues - CTCM acknowledged that the significant drop in net profit was influenced by tax payments totaling approximately 1.53 billion yuan for the years 2017 to 2023, with 1.02 billion yuan already paid [6][7]. - The tax payments are expected to reduce the net profit attributable to shareholders by about 129 million yuan [6]. Market and Strategic Challenges - The company faces intensified market competition and structural changes in demand, particularly due to the implementation of national centralized procurement policies [4][5]. - CTCM's R&D investment for 2024 was 596 million yuan, a decrease of 13.1% from the previous year, which may hinder its competitive position in the market [5]. Stock Performance and Privatization Attempts - CTCM's stock price has been under pressure, with a significant drop following failed privatization attempts by its controlling shareholder, China National Pharmaceutical Group [8][10]. - The stock price fell by 44.5% to 2.12 HKD after the privatization announcement failed, reflecting investor concerns about the company's future [8][10]. Regulatory Environment - The company is under increasing regulatory scrutiny, necessitating a stronger focus on compliance and quality assurance to regain market trust [7][11].